Bill & Melinda Gates Medical Research Institute

Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

Retrieved on: 
Thursday, August 10, 2023
Workforce, Therapy, Prevalence, Bill & Melinda Gates Medical Research Institute, MRI, Investigational New Drug, Patient, Investment, Colorectal cancer, SAN, ADC, Research, FDA, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Malaria, Pharmaceutical industry, Cryptocurrency

SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2023, and announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%. Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.

Key Points: 
  • As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%.
  • Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.
  • Atreca expects to nominate a clinical candidate from the program in 2023 and is targeting an IND submission in late 2024/early 2025.
  • Atreca reported a net loss of $19.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.49, for the quarter ended June 30, 2023.

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

Retrieved on: 
Monday, June 5, 2023
Vaccine, NVAX, Organization, Bill, Bill & Melinda Gates Medical Research Institute, Doctor of Philosophy, Research, COVID, Novavax, Malaria

GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.

Key Points: 
  • GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.
  • "We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts," said John C. Jacobs, President and Chief Executive Officer, Novavax.
  • "The Bill & Melinda Gates Medical Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need," said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute.
  • The Matrix-M adjuvant is a key component of Novavax's COVID vaccine and its development-stage vaccines including influenza and COVID and influenza combined.

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

Retrieved on: 
Monday, June 5, 2023
Vaccine, NVAX, Organization, Bill, Bill & Melinda Gates Medical Research Institute, Doctor of Philosophy, Research, COVID, Novavax, Malaria

GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.

Key Points: 
  • GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.
  • "We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts," said John C. Jacobs, President and Chief Executive Officer, Novavax.
  • "The Bill & Melinda Gates Medical Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need," said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute.
  • The Matrix-M adjuvant is a key component of Novavax's COVID vaccine and its development-stage vaccines including influenza and COVID and influenza combined.

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

Retrieved on: 
Wednesday, March 29, 2023
Therapy, Prevalence, CD3, Conference call, Telephone, Bill & Melinda Gates Medical Research Institute, Survival, Lung cancer, Bowel obstruction, EDT, Pain, PIN, MD, Patient, Investment, Colorectal cancer, Melanoma, Kaplan–Meier estimator, CR, Webcast, ADC, Growth, Research, Headache, IND, Conference, SD, PR, Safety, Fatigue, Malaria, Pharmaceutical industry, Vaccine, Cryptocurrency

SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided an overview of recent developments.

Key Points: 
  • "Last year was a productive time for Atreca, with advances made in our discovery platform, preclinical programs, and ATRC-101,” said John Orwin, Chief Executive Officer of Atreca.
  • All participants in the combination arm had experienced an unsatisfactory tumor response or progression following prior anti-PD-1 or anti-PD-L1 therapy.
  • Atreca and Xencor expect to name a candidate from the program in 2023 and target an IND submission by early 2025.
  • Atreca will host a live conference call and webcast, including accompanying slides, today at 4:30 p.m. EDT.

Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Other Health, Health, Clinical Trials, Oncology, Lorence, Infection, Immunotherapy, Vaccine, Bill & Melinda Gates Medical Research Institute, Engineering, Malaria, Gates, Tuberculosis, National Institute of Cholera and Enteric Diseases, Beth Israel Deaconess Medical Center, Autoimmune disease, Division, Third Rock Ventures, Inflammation, Head, Regulatory T cell, Autoimmunity, MRI, Therapy, Patient, Biology, Society, Developmental Leadership Program, Drug development, Harvard Medical School, Merck & Co., Research, Merck, Virology, Pharmaceutical industry, Medicine, Cancer

With prior tenures at the Bill and Melinda Gates Medical Research Institute and Merck Research Labs, David brings 20 years of experience in translational medicine and novel drug development to Abata’s board.

Key Points: 
  • With prior tenures at the Bill and Melinda Gates Medical Research Institute and Merck Research Labs, David brings 20 years of experience in translational medicine and novel drug development to Abata’s board.
  • He was previously chief medical officer and head of translational development at the Bill and Melinda Gates Medical Research Institute (MRI).
  • Previously, he led translational oncology at Merck Research Laboratories, where he oversaw immuno-oncology translational medicine, novel biomarker development, and global translational research partnering.
  • He is a director of Hookipa Pharma and a director ex officio of the Society for the Immunotherapy of Cancer.

Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate tuberculosis treatment compound

Retrieved on: 
Wednesday, February 15, 2023
Macrophage, Bill, Drug resistance, Cornell University College of Engineering, Veterinary medicine, Tuberculosis, Scripps Research, Microbiology, Carbon, Cholesterol, Cell, Scripps, Bill & Melinda Gates Medical Research Institute, Death, Immunology, Disease, Growth, Gates, Partnership, Mycobacterium tuberculosis, Infection, Max Planck Institute for Infection Biology, Research, TB, Drug discovery, Bill & Melinda Gates Foundation, Nix, Doctor of Philosophy, Pharmaceutical industry, Vaccine, MTB, National Accreditation Board for Testing and Calibration Laboratories

LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment. Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment. Calibr will transition CLB073 to Gates MRI for further development.

Key Points: 
  • LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.
  • Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment.
  • "At Calibr, we have been working with collaborators, through the support of the Bill & Melinda Gates Foundation, to discover and develop novel medicines for diseases that require improved treatment regimens, such as tuberculosis.
  • "Tuberculosis is one of the world's most significant infectious causes of human disease and death," said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute.

Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate tuberculosis treatment compound

Retrieved on: 
Wednesday, February 15, 2023
Macrophage, Bill, Drug resistance, Cornell University College of Engineering, Veterinary medicine, Tuberculosis, Scripps Research, Microbiology, Carbon, Cholesterol, Cell, Scripps, Bill & Melinda Gates Medical Research Institute, Death, Immunology, Disease, Growth, Gates, Partnership, Mycobacterium tuberculosis, Infection, Max Planck Institute for Infection Biology, Research, TB, Drug discovery, Bill & Melinda Gates Foundation, Nix, Doctor of Philosophy, Pharmaceutical industry, MTB, National Accreditation Board for Testing and Calibration Laboratories

LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment. Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment. Calibr will transition CLB073 to Gates MRI for further development.

Key Points: 
  • LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.
  • Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment.
  • "At Calibr, we have been working with collaborators, through the support of the Bill & Melinda Gates Foundation, to discover and develop novel medicines for diseases that require improved treatment regimens, such as tuberculosis.
  • "Tuberculosis is one of the world's most significant infectious causes of human disease and death," said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute.

Focused Ion Beam Market worth $1.8 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, December 20, 2022
Cloud, Organization, TEM, Ecosystem, USD, Hardware, Industrial, IPhone, Semiconductor device fabrication, Geography, Bill & Melinda Gates Medical Research Institute, Growth, A&D Company, FOCUS, JEOL, SEM, Enablement, GTM, Failure, FIB, Mindful Scientific Inc., Herty Advanced Materials Development Center, Forbes Global 2000, Geological Museum of the State Geological Institute, Foxconn, B2B, Principal Scientific Adviser to the Government of India, Electronics, Investment, Czech Republic, Research, Thermo Fisher Scientific, TESCAN, Hitachi, Mobile phone, Renewable energy, Microscope, Vedanta

The growth of the focused ion beam market can be attributed to requirement for ion beam lithography technology-integrated FIB systems and deployment of focused ion beam systems for applications in material science industry.

Key Points: 
  • The growth of the focused ion beam market can be attributed to requirement for ion beam lithography technology-integrated FIB systems and deployment of focused ion beam systems for applications in material science industry.
  • The failure analysis segment will record the highest CAGR in the focused ion beam market during the forecast period.
  • In 2022, the electronics & semiconductor vertical accounted for the largest share of the focused ion beam market.
  • The focused ion beam market in Asia Pacific is projected to grow at the highest CAGR during the forecast period.

Focused Ion Beam Market worth $1.8 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, December 20, 2022
Cloud, Organization, TEM, Ecosystem, USD, Hardware, Industrial, IPhone, Semiconductor device fabrication, Geography, Bill & Melinda Gates Medical Research Institute, Growth, A&D Company, FOCUS, JEOL, SEM, Enablement, GTM, Failure, FIB, Mindful Scientific Inc., Herty Advanced Materials Development Center, Forbes Global 2000, Geological Museum of the State Geological Institute, Foxconn, B2B, Principal Scientific Adviser to the Government of India, Electronics, Investment, Czech Republic, Research, Thermo Fisher Scientific, TESCAN, Hitachi, Mobile phone, Renewable energy, Microscope, Vedanta

The growth of the focused ion beam market can be attributed to requirement for ion beam lithography technology-integrated FIB systems and deployment of focused ion beam systems for applications in material science industry.

Key Points: 
  • The growth of the focused ion beam market can be attributed to requirement for ion beam lithography technology-integrated FIB systems and deployment of focused ion beam systems for applications in material science industry.
  • The failure analysis segment will record the highest CAGR in the focused ion beam market during the forecast period.
  • In 2022, the electronics & semiconductor vertical accounted for the largest share of the focused ion beam market.
  • The focused ion beam market in Asia Pacific is projected to grow at the highest CAGR during the forecast period.

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Investigational New Drug, Bill & Melinda Gates Medical Research Institute, Investment, U.S. Securities and Exchange Commission, Annual general meeting, Risk, Immunotherapy, Research, Society for Immunotherapy of Cancer, Bleeding, Malaria, RNA, SEC, Annual report, NASDAQ, Antibody, Compte rendu, CD3, Association, Company, Toxicity, Neoplasm, ADC, Patient, Immune system, Bill, Therapy, Security (finance), Society, NHP, SITC, Pharmaceutical industry, Vaccine, IND

"The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101, said John Orwin, Chief Executive Officer of Atreca.

Key Points: 
  • "The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101, said John Orwin, Chief Executive Officer of Atreca.
  • Atreca continued enrolling patients in its ongoing Phase 1b study of ATRC-101 based on ATRC-101 target expression in archival or newly obtained biopsies.
  • Atreca now expects to present updated monotherapy and combination data from the trial in the first quarter of 2023.
  • Research and development expenses for the quarter ended September 30, 2022, were $16.0 million, including non-cash share-based compensation expense of $1.9 million.